BRPI0418245A - nitróxi-derivados de prostaglandina - Google Patents

nitróxi-derivados de prostaglandina

Info

Publication number
BRPI0418245A
BRPI0418245A BRPI0418245-6A BRPI0418245A BRPI0418245A BR PI0418245 A BRPI0418245 A BR PI0418245A BR PI0418245 A BRPI0418245 A BR PI0418245A BR PI0418245 A BRPI0418245 A BR PI0418245A
Authority
BR
Brazil
Prior art keywords
nitroxy
prostaglandin derivatives
derivatives
prostaglandin
glaucoma
Prior art date
Application number
BRPI0418245-6A
Other languages
English (en)
Inventor
Ennio Ongini
Francesca Benedini
Valerio Chiroli
Piero Del Soldato
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34778199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0418245(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of BRPI0418245A publication Critical patent/BRPI0418245A/pt
Publication of BRPI0418245B1 publication Critical patent/BRPI0418245B1/pt
Publication of BRPI0418245B8 publication Critical patent/BRPI0418245B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

"NITROXI-DERIVADOS DE PROSTAGLANDINA". São descritos nitróxi-derivados de prostaglandinas tendo atividade farmacológica aumentada e tolerabilidade melhorada. Eles podem ser empregados para o tratamento de glaucoma e de hipertensão ocular.
BRPI0418245A 2004-01-05 2004-12-27 composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes BRPI0418245B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04100001 2004-01-05
PCT/EP2004/014820 WO2005068421A1 (en) 2004-01-05 2004-12-27 Prostaglandin nitrooxyderivatives

Publications (3)

Publication Number Publication Date
BRPI0418245A true BRPI0418245A (pt) 2007-04-17
BRPI0418245B1 BRPI0418245B1 (pt) 2017-05-30
BRPI0418245B8 BRPI0418245B8 (pt) 2021-05-25

Family

ID=34778199

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418245A BRPI0418245B8 (pt) 2004-01-05 2004-12-27 composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes

Country Status (39)

Country Link
US (5) US7273946B2 (pt)
EP (3) EP3643702A1 (pt)
JP (1) JP3984283B2 (pt)
KR (2) KR100854838B1 (pt)
CN (1) CN100469765C (pt)
AP (1) AP2006003638A0 (pt)
AR (2) AR047081A1 (pt)
AU (1) AU2004313688B2 (pt)
BR (1) BRPI0418245B8 (pt)
CA (1) CA2551409C (pt)
CR (2) CR8498A (pt)
CY (1) CY1117417T1 (pt)
DK (1) DK1704141T3 (pt)
EA (1) EA010595B1 (pt)
EC (1) ECSP066684A (pt)
ES (2) ES2767136T3 (pt)
GE (1) GEP20094780B (pt)
GT (1) GT200500293A (pt)
HR (1) HRP20160500T1 (pt)
HU (1) HUE027357T2 (pt)
IL (1) IL176416A (pt)
MA (1) MA28284A1 (pt)
ME (1) ME02433B (pt)
MX (1) MXPA06007678A (pt)
MY (1) MY147181A (pt)
NO (2) NO337217B1 (pt)
NZ (1) NZ548271A (pt)
OA (1) OA13356A (pt)
PA (1) PA8620901A1 (pt)
PE (1) PE20051052A1 (pt)
PL (1) PL1704141T3 (pt)
RS (1) RS54717B1 (pt)
SI (1) SI1704141T1 (pt)
TN (1) TNSN06210A1 (pt)
TW (1) TWI337994B (pt)
UA (1) UA84726C2 (pt)
UY (1) UY28709A1 (pt)
WO (1) WO2005068421A1 (pt)
ZA (1) ZA200605354B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2767136T3 (es) 2004-01-05 2020-06-16 Nicox Sa Derivados de prostaglandinas
JP2009500315A (ja) * 2005-06-29 2009-01-08 ファイザー・インク フルオロプロスタグランジンのニトロ誘導体
EP1899295A2 (en) * 2005-06-29 2008-03-19 Pfizer, Inc. Prostaglandin derivatives
CA2647859C (en) * 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
DE102006052755A1 (de) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
WO2008071421A1 (en) * 2006-12-15 2008-06-19 Nicox S.A. Nitrate esters of carbonic anhydrase inhibitors
US20100063035A1 (en) 2006-12-15 2010-03-11 Nicox S.A. Carbonic anhydrase inhibitors derivatives
WO2008149181A1 (en) 2007-06-04 2008-12-11 Techfields Inc Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
WO2009035565A1 (en) * 2007-09-07 2009-03-19 Qlt Plug Delivery, Inc Prostaglandin analogues for implant devices and methods
EP2214482A4 (en) * 2007-10-31 2011-08-24 Pamela Lipkin COMPOSITIONS OF PROSTAGLANDIN ANALOGUES AND METHODS OF TREATING EPITHELIAL STATES
AR076731A1 (es) * 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
US7807716B2 (en) * 2008-09-24 2010-10-05 Oral Delivery Technology Ltd. Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use
RU2630577C2 (ru) 2008-12-04 2017-09-11 Чунси ЮЙ Композиции интенсивного проникновения и их применение
KR101172638B1 (ko) 2008-12-30 2012-08-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
CN102498088A (zh) * 2009-09-15 2012-06-13 帝斯曼知识产权资产管理有限公司 硝基氧基酯及其制备和用途
CN101885684B (zh) * 2010-07-01 2013-10-30 南京中医药大学 带有一氧化氮供体的芳香酸前体药物及其制备方法和其应用
ES2727203T3 (es) 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
HU231203B1 (hu) * 2011-12-21 2021-10-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Új eljárás travoprost előállítására
CA2872338C (en) 2012-05-03 2021-09-14 Qlt Inc. Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
US9446015B2 (en) * 2012-10-23 2016-09-20 Nicox Science Ireland Quinone based nitric oxide donating compounds for ophthalmic use
JP6306148B2 (ja) * 2013-04-18 2018-04-04 ニコックス サイエンス アイルランド 点眼用のキノン系一酸化窒素供与性化合物
EP3091985B1 (en) 2014-01-10 2024-05-08 Manistee Therapeutics, Inc. Prostanglandins for topical use in the treatment of migraines.
CA2964364A1 (en) * 2014-10-15 2016-04-21 Novartis Ag Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension
WO2016155906A1 (en) * 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of fluprostenol
US10047047B2 (en) 2015-03-31 2018-08-14 Nicox S.A. Nitric oxide donating derivatives of latanoprost free acid
EP3088388A1 (en) 2015-04-30 2016-11-02 NicOx S.A. Nitric oxide donating derivatives of prostaglandins
EA037327B1 (ru) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Соединения и композиции для лечения глазных расстройств
HU231175B1 (hu) * 2015-12-04 2021-06-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Tetszőleges, előre meghatározott minőségű Latanoprostene bunod előállítása gravitációs kromatográfiával
CA3043000A1 (en) 2016-11-08 2018-05-17 Bausch & Lomb Incorporated Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma
KR102069205B1 (ko) * 2017-08-09 2020-01-22 연성정밀화학(주) 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체
RU2718744C2 (ru) * 2018-05-17 2020-04-14 Общество с ограниченной ответственностью "Гурус БиоФарм" Производные простагландина F2альфа для снижения внутриглазного давления
CN109988089B (zh) * 2018-05-29 2022-04-26 上海凡秦医药科技有限公司 一种前列腺素化合物、制备方法及其用途
CN108892624B (zh) * 2018-06-20 2020-12-15 重庆威鹏药业有限公司 沙库巴曲硝基氧衍生物及其制备方法和应用
ES2964005T3 (es) * 2019-08-05 2024-04-03 Nicox Sa Procedimiento de preparación de un análogo de prostaglandina donador de óxido nítrico
US11332433B2 (en) 2020-07-24 2022-05-17 Chirogate International Inc. Process for the preparation of latanoprostene bunod and intermediate thereof and compositions comprising the same
CN113943266A (zh) * 2021-11-18 2022-01-18 广州楷石医药有限公司 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途
CN116444377A (zh) * 2022-01-07 2023-07-18 广州楷石医药有限公司 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途
CA3195291A1 (en) * 2022-04-13 2023-10-13 Caravel Therapeutics, Inc. Preservative-free ophthalmic pharmaceutical emulsion and its application

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922293A (en) 1971-12-30 1975-11-25 Upjohn Co Prostaglandin F-type 9-monoacylates
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
EP1348437A3 (en) 1988-09-06 2003-11-19 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
DE69311361T2 (de) 1992-10-13 1998-01-08 Alcon Lab Inc Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
US5328933A (en) * 1992-10-28 1994-07-12 Allergan, Inc. Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
US5625083A (en) * 1995-06-02 1997-04-29 Bezuglov; Vladimir V. Dinitroglycerol esters of unsaturated fatty acids and prostaglandins
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292377B1 (it) * 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
US6417228B1 (en) 1998-11-02 2002-07-09 Alcon Manufacturing, Ltd.. 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
US20030018079A1 (en) 2000-11-13 2003-01-23 Richardson Helene Treatment
BR0209063A (pt) * 2001-04-19 2004-08-10 Teika Pharmaceutical Co Ltd Medicamentos e kits de uso medicinal
ES2767136T3 (es) 2004-01-05 2020-06-16 Nicox Sa Derivados de prostaglandinas

Also Published As

Publication number Publication date
NZ548271A (en) 2010-01-29
ES2767136T3 (es) 2020-06-16
UY28709A1 (es) 2005-08-31
CR20110131A (es) 2011-03-30
SI1704141T1 (sl) 2016-04-29
JP3984283B2 (ja) 2007-10-03
US20100130507A1 (en) 2010-05-27
TNSN06210A1 (fr) 2007-12-03
HRP20160500T1 (hr) 2016-06-03
EP3002277A1 (en) 2016-04-06
WO2005068421A1 (en) 2005-07-28
NO20151341A1 (no) 2006-09-07
ME02433B (me) 2016-09-20
BRPI0418245B8 (pt) 2021-05-25
MXPA06007678A (es) 2006-09-01
AU2004313688B2 (en) 2010-08-05
BRPI0418245B1 (pt) 2017-05-30
TW200526567A (en) 2005-08-16
EA200601099A1 (ru) 2006-10-27
DK1704141T3 (en) 2016-05-02
ES2566800T3 (es) 2016-04-15
EP3643702A1 (en) 2020-04-29
US7273946B2 (en) 2007-09-25
ZA200605354B (en) 2009-09-30
MY147181A (en) 2012-11-14
EA010595B1 (ru) 2008-10-30
EP1704141A1 (en) 2006-09-27
CA2551409A1 (en) 2005-07-28
US20110136904A1 (en) 2011-06-09
MA28284A1 (fr) 2006-11-01
ECSP066684A (es) 2006-10-25
KR100854838B1 (ko) 2008-08-29
US7629345B2 (en) 2009-12-08
PA8620901A1 (es) 2005-08-30
GT200500293A (es) 2007-07-06
OA13356A (en) 2007-04-13
HK1096084A1 (zh) 2007-05-25
EP3002277B1 (en) 2019-11-06
PE20051052A1 (es) 2005-12-17
EP1704141B1 (en) 2016-02-24
AP2006003638A0 (en) 2006-06-30
AR047081A1 (es) 2006-01-04
IL176416A (en) 2013-05-30
GEP20094780B (en) 2009-09-25
US20090030076A1 (en) 2009-01-29
AU2004313688A1 (en) 2005-07-28
CN100469765C (zh) 2009-03-18
US20050272743A1 (en) 2005-12-08
RS54717B1 (sr) 2016-08-31
NO20063567L (no) 2006-09-07
JP2007518716A (ja) 2007-07-12
KR20080007415A (ko) 2008-01-18
NO337217B1 (no) 2016-02-15
US7449469B2 (en) 2008-11-11
CR8498A (es) 2006-11-15
KR100850133B1 (ko) 2008-08-04
KR20060113753A (ko) 2006-11-02
UA84726C2 (ru) 2008-11-25
CY1117417T1 (el) 2017-04-26
US20080058392A1 (en) 2008-03-06
CN1906159A (zh) 2007-01-31
IL176416A0 (en) 2006-10-05
WO2005068421A8 (en) 2006-02-09
US7910767B2 (en) 2011-03-22
PL1704141T3 (pl) 2016-08-31
US8058467B2 (en) 2011-11-15
NO339685B1 (no) 2017-01-23
TWI337994B (en) 2011-03-01
HUE027357T2 (en) 2016-09-28
CA2551409C (en) 2011-02-22
AR098931A2 (es) 2016-06-22

Similar Documents

Publication Publication Date Title
MY147181A (en) Prostaglandin derivatives.
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
ATE299493T1 (de) N-cyanomethylamide als protease inhibitoren
BR0313747A (pt) Inibidores de transcriptase reversa de não-nucleosìdeo
ATE384058T1 (de) Thiazolderivate
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
SE0101932D0 (sv) Pharmaceutical combinations
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
CY1106409T1 (el) Παραγωγα κινολινης
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
SE0102055D0 (sv) New Compounds
AR026708A1 (es) Derivados de 5-hidroxi-indazol para el tratamiento de glaucoma
DE60325377D1 (de) Motilidverbindungen
TW200730179A (en) Prostaglandin derivatives
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600456A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
SE9401087D0 (sv) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
NO20035043D0 (no) Fremgangsmåte for behandling av okular hypertensjon og glaukom
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
EA200600250A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2860 DE 28/10/2025 POR TER SIDO INDEVIDA.